Rights Issue October-November 2019

Oncology Venture expects to raise in excess of SEK 100 million during the Autumn of 2019.

Rights issue overview

Following the approval of the share issue on the Extraordinary General Meeting on October 15, 2019, Oncology Venture intends to increase the company’s share capital.

A rights issue with pre-emptive rights: 
In brief, for every 7 shares a shareholder owns, the shareholder will have the right to subscribe to 5 new shares at a price of SEK 2/share. If all rights are utilized this will raise a total of SEK 
101,010,712 to Oncology Venture (before any cost related to the issuance). 

In addition, each investor subscribing to new shares will also receive 1 warrant for each new share. Each warrant will give a right, but no obligation, to buy a new share at a price of 6 SEK, at one or more specified date ranges during 2020-2021. The warrants will have a duration of 24 months. 

The general formula for calculating how many new shares a current shareholder will have the right to buy is: (number of shares currently owned)/7*5 = the number of shares which can be bought at 2 SEK/each, as well as the number of warrants the shareholder will receive. 

The share issue will be based on the EGM deciding to resolve the relevant resolutions regarding issue of shares with and without preemptive rights as well as issuance of warrants, as described in agenda items 3, 4 and 6.

Time table of extended subscription period

Last day of trading of existing shares with subscription rights

The last day of trading of existing shares with subscription rights is 25 October 2019. 

First day of trading of existing shares without subscription rights
The first day of trading of existing shares without subscription rights is 28 October
Record date for allocation of subscription rights
The record date is 29 October 2019.
Trading period for subscription rights on Nasdaq First North

31 October – 19 November 2019.

Subscription period for offer units

31 October – 21 November 2019.

Trading date for BTUs
31 October 2019, until registration of the capital increase.

Meet the new Company Management

Meet the new CEO, Steve Carchedi, and CFO, Henrik Moltke, at a series of investor presentations.
25th of October, Online

Pressträff Direkt
Time: November 25 at 2 pm. 
Place: Online on Youtube.

29th of October, Stockholm, Sweden

Venue: GT30, Turbin, Grev Turegatan 30, Stockholm
Time: 17:45 – 20:00​

30th of October, Gothenburg, Sweden

Venue: Elite Hotel
Time: 17:45 – 20:00

31th of October, Malmö, Sweden

Venue: High Court Hotel.
Time: 17:45 – 20:00

1st of November, Holte, Denmark

Time: November 1, 16:00-17:00.
Place: Hotel Comwell, Holte

Light snacks and drinks will be served.

5th of November, Stockholm, Sweden

Time: November 5, 17:45-20:00.
Place: Grev Turegatan 30.

6th of November, Online Q&A

Time: November 6, 16:00.
Place: https://www.proinvestor.com => Q&A

7th of November, Online Investor Presentation

Time: November 7, 19:00.
Place: Live online investor presentation.

Watch a video explaining the pre-emptive share issue:

The main purpose of the capital raise is to ensure the further development the company's pipeline. The financing will be spent in a highly prioritized manner.

Sign up for press releases and receive relevant information about Oncology Venture A/S